Friday, January 24, 2014

Ranbaxy Drugs at Fourth Plant Banned From U.S. Market

Ranbaxy Laboratories Ltd. can’t make or distribute drug ingredients from a fourth plant in India for the U.S. market, regulators ordered.

A U.S. Food and Drug Administration inspection of Ranbaxy’s Toansa facility found that workers retested drug products to produce acceptable findings after the items originally failed analytical testing.